GEN-MKT-18-7897-A
Feb 17, 2022 | Blogs, Environmental / Industrial | 0 comments
In a recent PFAS fireside chat, Dr. John Washington from the US EPA discussed the findings of a recent study published in Science that detected a novel group of per- and polyfluoroalkyl substances (PFAS)—called chloroperfluoropolyether carboxylates (ClPFPECAs)—in soil samples from New Jersey. The study, conducted by Dr. Washington and his colleagues, detected 10 unique ClPFPECAs in these samples, with the highest concentrations measured near the Solvay manufacturing plant in West Deptford Townhouse, New Jersey, and decreased amounts detected as the distance from the plant increased.
What did the PFAS study find?
The detected novel ClPFPECAs were found to be structurally similar to many of the well-known “legacy” PFAS compounds, such as perfluorooctanoic acid (PFOA), but with notable exceptions. First, in ClPFPECAs, one of the fluorine atoms is replaced by a chlorine near the end of the molecule, which is what makes them “chloroperfluoro-” compounds. Second, ClPFPECAs contain two ether groups in the carbon backbone. However, ClPFPECAs are similar to PFOA in that they contain carboxylic acid functional groups.
So, why were these ClPFPECAs found near the Solvay plant? As noted in the paper, these novel PFAS chemicals are used as processing aids in the manufacturing of fluoropolymers. Previously, Solvay made its fluoropolymers using Surflon, which contains C9, C11 and C13 perfluorinated carboxylic acids (PFCAs). In 2016, however, several manufacturers, including Solvay, agreed to phase out these long-chain PFCAs. It is uncertain, but the ClPFPECAs detected in the study may be used as replacement compounds for Surflon.
For this study, the research team used a combination of targeted and non-targeted analytical techniques. As noted by Dr. Washington, the non-targeted analysis methods were essential to finding these novel PFAS compounds. For example, the distinctive isotope signature of chlorine was used to confirm its presence in the molecules. In addition, techniques such as Kendrick mass defect analysis and the identification of common, diagnostic fragments were used to find other ClPFPECAs in the soil samples.
What do the findings improve our understanding of PFAS risks?
So, what happens to these novel PFAS in the environment? While that’s still unclear, Dr. Washington’s group is involved in investigating transformation at the chlorine site of the molecule, which may indicate that the ClPFPECAs can form other novel PFAS. Stay tuned for the results of this research.
Although the ultimate risk of ClPFPECAs to human and wildlife health remains unknown, this study eloquently demonstrates how mass spectrometry—specifically high resolution accurate mass spectrometry instruments—can be used to improve our understanding of the PFAS “dark matter” that exists in our environment.
*This content does not constitute legal advice. You should consult counsel to assure your procedures comply with applicable law and that it meets your needs.
RUO-MKT-18-14241-A
In monoclonal antibody (mAb) development, assessment of purity and integrity of the protein in question is critical. CE‑SDS is the gold standard assay and is routinely run from analytical development through QC and lot release. It’s trusted because it consistently delivers quantitative, size‑based insight into purity and fragmentation, and it fits naturally into regulated environments.
In drug discovery and development, Metabolite Identification (Met ID) plays a critical role in understanding biotransformation pathways, ensuring safety, and meeting regulatory requirements. Advanced mass spectrometry techniques have revolutionized this process, particularly through electron-based fragmentation methods such as Electron Activated Dissociation (EAD) and Electron Transfer Dissociation (ETD). While both techniques leverage electron interactions to generate informative fragment ions, they differ significantly in mechanism, performance, and suitability for Met ID workflows.
In analytical laboratories, performance is not optional. Whether supporting regulated pharmaceutical workflows, high-throughput CRO operations, clinical reporting, or food and environmental testing, your mass spectrometry and capillary electrophoresis systems are critical to productivity, compliance, and scientific confidence.
Posted by
You must be logged in to post a comment.
Share this post with your network